# A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer

> **NCT03749083** · — · WITHDRAWN · sponsor: **Massachusetts General Hospital**

## Conditions studied

- Gastrointestinal Malignancies

## Interventions

- **OTHER:** The Functional Assessment of Cancer Therapy- Colorectal

## Key facts

- **NCT ID:** NCT03749083
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12-31
- **Primary completion:** 2021-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding
- **Last updated:** 2019-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03749083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03749083, "A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT03749083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*